A small regulatory company had been commissioned to review the development data package available from a US biotech company for a liquid inhalation product, with a view to using the data package for a New Drug Application submission. The regulatory company approached us asking for a gap analysis of the data package in relation to a European product license submission.
Our CMC consultant reviewed the CMC data package and provided the analysis, enabling the client to gain a clear picture of any gaps and respond as necessary before making the submission.